News
GILD
66.16
-1.15%
-0.77
Gilead Sciences Is Maintained at Neutral by UBS
Dow Jones · 15h ago
Gilead Sciences Price Target Cut to $75.00/Share From $81.00 by UBS
Dow Jones · 15h ago
Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns
TipRanks · 17h ago
GILEAD SCIENCES INC <GILD.O>: UBS CUTS TARGET PRICE TO $75 FROM $81
Reuters · 1d ago
ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary
U.S. Equities continued their upward march in the first quarter as the momentum rally showed few signs of flagging. ClearBridge was active in seizing opportunities as a concentrated market left pockets where excellent assets were undervalued. The Strategy delivered strong absolute performance driven by industrials and consumer discretionary holdings.
Seeking Alpha · 1d ago
Pfizer's Doldrums, Just A Bad Case Of COVID-19?
Pfizer's dividend has reached the sky-high 6% mark. The company is following a similar trajectory to GILD in its post-HCV stagnation. PFE may be worth buying as the company's COVID-based product revenues decline and equilibrate. Company is working to develop a vaccine for the pandemic.
Seeking Alpha · 2d ago
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
NASDAQ · 2d ago
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Three Nasdaq-100 stocks with high dividend yields are among the top three dividend payers on the Nasdaq 100. Walgreens Boots Alliance, Gilead Sciences and Kraft Heinz are the other two. The stock market rally may be running out of steam, but dividend stocks can be a good way to ride out volatility.
The Motley Fool · 3d ago
Should You Invest in the VanEck Biotech ETF (BBH)?
NASDAQ · 3d ago
Weekly Report: what happened at GILD last week (0408-0412)?
Weekly Report · 3d ago
Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know
NASDAQ · 6d ago
Stocks with the highest swings in option premium price over 3 months - JPM
J.P. Morgan analysts listed stocks with the highest range bound score to identify those with the most swings in price over the past three months. These stocks have a rangebound score higher than 125%. Stocks with highest swings in option premium price over 3 months include Humana, General Electric and GE.
Seeking Alpha · 6d ago
BUZZ-Nurix Therapeutics drops after upsized $175 mln stock offering
Nurix Therapeutics Inc's shares down 5.3% at $16.30 premarket after upsized $175 mln stock offering. Biopharma firm Nurix announced 11.7 mln shares to be sold at $15 each. Nurix shares closed up 27% last week.
Reuters · 6d ago
U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map
As of April 11, there were 158 U.S. Wide-moat stocks meeting Morningstar's criteria. Only 4.4% of these stocks earned a 5-star valuation rating. The heat map of the most investable candidates lists the best companies on sale. We focus on the most attractively valued stocks with a wide- moat rating.
Seeking Alpha · 6d ago
Attractive call buying opportunities for Russell 1000 stocks - JPM
Seeking Alpha · 04/11 17:51
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its weakness. Verve Therapeutics Inc is one of the major oversold players in this sector.
Benzinga · 04/11 12:46
Gilead Sciences: Robust HIV Business and Oncology Growth Potential Justify Buy Rating
TipRanks · 04/11 09:57
ClearBridge Value Equity Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Value Equity Strategy Q1 2024 Portfolio Manager Commentary: We seek to generate attractive returns in the most attractive market environments. The fund is a leading global asset manager with a long-term focus on utilities and other value-oriented investments. ClearBridge Value Fund A is expected to be closed to new investments in the first quarter of 2024.
Seeking Alpha · 04/10 16:50
GILEAD SCIENCES INC. <GILD.O>: MORGAN STANLEY CUTS TARGET PRICE TO $80.00 FROM $83.00
Reuters · 04/10 14:48
GILD Factor-Based Stock Analysis
NASDAQ · 04/10 14:06
More
Webull provides a variety of real-time GILD stock news. You can receive the latest news about Gilead Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.